Company
Charles River Laboratories International, Inc.
Headquarters: Wilmington, MA, United States
Founded: 1947
Employees: 18,600
CEO: Mr. James C. Foster J.D.
Market Cap
$10.28 Billion
USD as of July 1, 2024
Charles River Laboratories International, Inc. Categories
United States Healthcare Diagnostics & ResearchUnited States Healthcare United States Diagnostics & Research
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $204.45 B |
| Danaher | $177.21 B |
| Siemens Healthineers AG | $63.84 B |
| DexCom, Inc. | $45.21 B |
| Lonza Group Ltd | $39.85 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Charles River Laboratories International, Inc. has the following listings and related stock indices.
Stock: NYSE: CRL wb_incandescent
Stock: FSX: RV6 wb_incandescent
Key People
James C. Foster (CEO)
Financials
Revenue: US$2.923 billion (Fiscal Year Ended December 26, 2020)
Operating income: US$432.729 million (Fiscal Year Ended December 26, 2020)
Net income: US$364.304 million (Fiscal Year Ended December 26, 2020)
Total assets: US$5.490 billion (Fiscal Year Ended December 26, 2020)
Total equity: US$2.118 billion (Fiscal Year Ended December 26, 2020)